

BIOMARIN PHARMACEUTICAL INC

Form 4

July 03, 2007

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Swiedler Stuart J

2. Issuer Name and Ticker or Trading
Symbol

BIOMARIN PHARMACEUTICAL
INC [BMRN]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction
(Month/Day/Year)

07/02/2007

____ Director ____ 10% Owner
____X____ Officer (give title below) ____ Other (specify below)

SVP, Clinical Affairs

C/O BIOMARIN
PHARMACEUTICAL INC., 105
DIGITAL DRIVE

(Street)

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)

____X____ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

NOVATO, CA 94949

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price		
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	M		12,500	A	\$ 4	22,500	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S		100	D	\$ 18.12	22,400	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S		1,150	D	\$ 18.121	21,250	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S		450	D	\$ 18.131	20,800	D
	07/02/2007 ⁽¹⁾	07/02/2007	S		300	D	\$ 18.14	20,500	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common
Stock

Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	600	D	\$ 18.15	19,900	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	1,750	D	\$ 18.161	18,150	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	900	D	\$ 18.17	17,250	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	1,250	D	\$ 18.09	16,000	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	300	D	\$ 18.151	15,700	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	200	D	\$ 18.16	15,500	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	1,100	D	\$ 18.18	14,400	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	450	D	\$ 18.181	13,950	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	200	D	\$ 18.19	13,750	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	400	D	\$ 18.2	13,350	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	450	D	\$ 18.201	12,900	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	400	D	\$ 18.21	12,500	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	100	D	\$ 18.26	12,400	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	1,150	D	\$ 18.261	11,250	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	100	D	\$ 18.27	11,150	D
Common Stock	07/02/2007 ⁽¹⁾	07/02/2007	S	1,150	D	\$ 18.271	10,000	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
Stock Option (right to buy)	\$ 4	07/02/2007	07/02/2007	M	12,500	12/24/1998 ⁽²⁾ 06/14/2008	Common Stock	12,500

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Swiedler Stuart J C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			SVP, Clinical Affairs	

Signatures

/s/ G. Eric Davis,
Attorney-in-Fact

07/03/2007

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Transaction made pursuant to Rule 10b5-1 Trading Plan.

(2) Options vest 6/48ths on 12/24/1998 and 1/48th on the 24th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.